Biotech companies are exploring ways to slow aging, with Rubedo Life Sciences focusing on skin. Their experimental cream, tested on 11 people with eczema, targets senescent cells—damaged cells that stop dividing but don’t die, contributing to aging and inflammation. After four weeks, participants’ skin appeared two years younger on average, with one person seeing an 11-year reduction. The treatment also reduced inflammation markers and increased collagen, improving skin elasticity. This approach targets a protein to make senescent cells more prone to cell death while helping nearby stressed cells recover. Rubedo’s work is part of a broader effort to tackle aging by removing harmful cells.
QUESTION: How might advancements in anti-aging treatments impact the way society views aging and the elderly?
A New Anti-Aging Drug Looks to Turn Back the Clock on Skin Age
